Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 445-453

  Esteban, Rafael ^a   Buti, Maria ^a  

^a HOSPITAL GENERAL DE CATALUNYA   (Spain)

Author keywords

Boceprevir; Hepatitis C; Naive; Telaprevir

Indexed keywords

BOCEPREVIR; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; DIHYDROPYRIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANAL COMPLAINT; ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID VIROLOGIC RESPONSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84870450569     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.001     Document Type: Article

References (23)

1. M.P. Manns, J.G. McHutchinson, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
2. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Gonçales Jr. Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
4. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
5. F. Poordad, J. McCone Jr., B.R. Bacon, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
6. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
7. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
8. FDA Background material for boceprevir advisory committee division of antiviral products (DAVP) April 27, 2011 http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AntiviralDrugsAdvisoryCommittee/UCM252341.pdf [accessed 15.11.11]
9. M.L. Shiffman HCV response guided therapy: should treatment length be shortened or extended? Curr Hepat Rep 10 2011 4 10
10. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, and U. Karey Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 Dec 1709 1718
11. M.W. Fried, S.J. Hadziyannis, M.L. Shiffman, D. Messinger, and S. Zeuzem Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection J Hepatol 55 2011 69 75
12. T. Berg Tailored treatment for hepatitis C. Clin Liver Dis 12 2008 507 528
13. S. Susser, J. Vermehren, N. Forestier, M.W. Welker, N. Grigorian, and C. Füller Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir J Clin Virol 41 2011 321 327
14. C. Sarrazin, H.W. Reesink, S. Zeuzem, C.J. Weegink, D. Lou, and J. Witek Retreatment with TVR/Peg-IFN/RBV after a short exposure to TVR in phase I studies: interim results from a phase IIb rollover trial (C219) Hepatology 54 Suppl. S1:S35 2011
15. J.J. Kiser, J.R. Burton, P.L. Anderson, and G. Everson Review and management of drug interactions with boceprevir and telaprevir Hepatology 5 2012 1620 1626
16. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seef An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
17. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
18. A.J. Thompson, A.J. Muir, M.S. Sulkowski, K. Patel, H.L. Tillmann, and P.J. Clark IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients Gastroenterology 139 2010 120 129
19. N.H. Afdhal, J.G. McHutchison, S. Zeuzem, A. Mangia, J.M. Pawlotsky, and J.S. Murray Hepatitis C pharmacogenetics: state of the art in 2010 Hepatology 53 2011 336 345
20. F. Poordad, J.P. Bronowicki, S.C. Gordon, S. Zeuzem, I.M. Jacobson, and M.S. Sulkowski IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy J Hepatol 54 2011 S6
21. I.M. Jacobson, I. Catlett, P. Marcellin, N.H. Bzowej, A.J. Muir, and N. Adda Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial J Hepatol 54 2011 S542
22. P. Marcellin, X. Forns, T. Goeser, P. Ferenci, F. Nevens, and G. Carosi Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C Gastroenterology 140 2011 459 468
23. J.P. Bronowicki, C. Hézode, L. Bengtsson, S. Pol, M. Bourlière, and L. Serfaty 100% SVR in IL28B SNP rs12979860 C/C patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial J Hepatol 56 Suppl. 2 2012 S430 S431